

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### comparison of the effect of combined intralesional Triamcinolone with topical Bimatoprost versus intralesional Triamcinolone or topical Bimatoprost in the treatment of alopecia areata

#### Protocol summary

##### Study aim

Determination and comparison of the improvement of alopecia areata lesion site based on PGA score, SALT score, and dermoscopic findings in the three studied groups, controlling for the possible effect of age, gender, and lesion site.

##### Design

3 parallel-group, single-blind, randomized, phase 3 clinical trial on 42 patients. A sealed envelope site was used for randomization.

##### Settings and conduct

This study includes 48 patients with alopecia areata referred to the clinic of Imam Khomeini Hospital. Evaluation of lesions by dermoscopy and photography will be performed before the start of treatment and one month after the last stage of treatment. It is single-blind, meaning that the physician evaluating the results will be unaware of the treatment method used.

##### Participants/Inclusion and exclusion criteria

Patients over 18 years of age who have at least one patch of alopecia areata and have not received treatment in the last three months and do not have any contraindications to treatment such as pregnancy, breastfeeding, and local allergy or infection.

##### Intervention groups

The first group will be treated with intralesional triamcinolone injection (5mg/ml for scalp alopecia and 2.5mg/ml for facial alopecia), the second group will be treated with bimatoprost 0.01% every 12 hours, and the third group will be treated with a combination of monthly triamcinolone injection and topical bimatoprost.

##### Main outcome variables

Age; Gender; Lesion site improvement based on Physician Assessment System (PGA) score; Patient satisfaction; Dermoscopy findings; SALT scoring

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20251014067632N1**

Registration date: **2026-04-28, 1405/02/08**

Registration timing: **registered\_while\_recruiting**

Last update: **2026-04-28, 1405/02/08**

Update count: **0**

##### Registration date

2026-04-28, 1405/02/08

##### Registrant information

##### Name

Negin Soozangar

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 61 3292 1837

##### Email address

negin.sgr@gmail.com

##### Recruitment status

**recruiting**

##### Funding source

##### Expected recruitment start date

2026-02-03, 1404/11/14

##### Expected recruitment end date

2026-07-05, 1405/04/14

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

## Scientific title

comparison of the effect of combined intralesional Triamcinolone with topical Bimatoprost versus intralesional Triamcinolone or topical Bimatoprost in the treatment of alopecia areata

## Public title

effect of bimatoprost on alopecia areata

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

□ People over 18 years of age with the hair loss pattern of alopecia areata who have at least one or more patches of alopecia. □ Consent to participate in the study.

### Exclusion criteria:

□ Sensitivity to the medications used. □ Pregnancy and breastfeeding. □ Systemic treatment has been performed within the past 3 months or topical treatment has been performed within the past 2 weeks. □ The site of application of the medicine is infected. □ Patients with pattern universalis or ophiasis or totalis □ Patients with spontaneous hair regrowth in the area of hair loss □ Patients with other dermatological diseases simultaneously

## Age

From **18 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

- Outcome assessor

## Sample size

Target sample size: **42**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Using the randomization method, patients are divided into three groups. A sealed envelope site is used to divide patients, and randomization is performed in blocks, and each block consists of 6 patients and includes 2 groups A, 2 groups B, and 2 groups C. In order to eliminate the effect of the interpretation of the researcher and the performing physician, in addition to observing blinding, the technique of concealing the allocation of numbers and letters was used, and the names of the groups were hidden.

## Blinding (investigator's opinion)

Single blinded

## Blinding description

The physician evaluating the results will be unaware of the treatment method used. At the beginning of treatment and one month after the last session, photographs of the lesions will be taken using a Xiaomi Redmi note11 pro mobile phone at a distance of 30 cm.

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Ahvaz Jundishapur University of Medical Sciences

##### Street address

No.2004, Unit 10, 5th Floor, Asadi8 Complex, 48 Daneshjoo St., daneshgah Town

##### City

ahwaz

##### Province

Khouzestan

##### Postal code

6134933357

#### Approval date

2024-10-28, 1403/08/07

#### Ethics committee reference number

IR.AJUMS.REC.1404.303

## Health conditions studied

### 1

#### Description of health condition studied

alopecia areata

#### ICD-10 code

L63

#### ICD-10 code description

Alopecia areata

## Primary outcomes

### 1

#### Description

amount of change in the SALT score (from 0 to 100).

#### Timepoint

At the beginning of treatment and one month after the end of treatment

#### Method of measurement

According to the areas involved in the scalp /left side:18% , right side=18%// ,top=40%,back=24 / (S0=no hair loss/ s1=<25% hair loss/ s2= 25%-49% hair loss/ s3=50%-74% hair loss/ s4=75-99%hairloss/ s5=100% total scalp hair loss)

### 2

#### Description

Changes in dermoscopy findings

#### Timepoint

At the beginning of treatment and one month after the end of treatment

### Method of measurement

Based on the researcher's observation (determining the number of black dots, yellow dots, broken hairs, exclamation mark hairs, villous hairs)

### 3

#### Description

Checking the rate of change in GPA score

#### Timepoint

At the beginning of treatment and one month after the end of treatment

#### Method of measurement

Evaluation of patient outcomes by a physician outside the study based on the response rate to treatment using photographs taken before and one month after treatment (from 0 to 4) (A0 = no improvement / A1 = poor response <25% / A2 = good response 25 to 50% / A3 = very good response 50 to 75% / A4 = excellent response 75 to 100%)

### Secondary outcomes

empty

### Intervention groups

#### 1

#### Description

Control group: was treated with intralesional triamcinolone injection (5mg/ml for scalp alopecia and 2.5mg/ml for facial alopecia) monthly for three months.

#### Category

Treatment - Drugs

#### 2

#### Description

Intervention group: Under treatment with bimatoprost 0.01% every 12 hours for three months

#### Category

Treatment - Drugs

#### 3

#### Description

Intervention group: Under combination treatment of monthly triamcinolone injections and topical bimatoprost every 12 hours for three months

#### Category

Treatment - Drugs

### Recruitment centers

#### 1

#### Recruitment center

##### Name of recruitment center

Imam Khomeini hospital

##### Full name of responsible person

Tara Barat

##### Street address

Imam Khomeini hospital, azadegan st.

##### City

ahwaz

##### Province

Khouzestan

##### Postal code

6193673166

##### Phone

+98 61 3292 1837

##### Email

negin.sgr@gmail.com

### Sponsors / Funding sources

#### 1

#### Sponsor

##### Name of organization / entity

Ahvaz University of Medical Sciences

##### Full name of responsible person

dr.abdollah rafeai

##### Street address

Ahvaz Jundishapur University, North Esfand Street, Golestan Alley

##### City

ahwaz

##### Province

Khouzestan

##### Postal code

6135715794

##### Phone

+98 61 3373 8383

##### Email

itc@ajums.ac.ir

##### Web page address

<https://vchresearch.ajums.ac.ir/>

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Ahvaz University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

### Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Ahvaz University of Medical Sciences

##### Full name of responsible person

Negin Soozangar

**Position**

Dermatology Assistant

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Dermatology

**Street address**

Unit 10, 5th floor, asadi8 complex, No.2009,  
daneshjoo 48 street, daneshgah town, ahvaz

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

6134933357

**Phone**

+98 61 3292 1837

**Fax****Email**

negin.sgr@gmail.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Negin Soozangar

**Position**

Dermatology Assistant

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Dermatology

**Street address**

Unit 10, 5th floor, asadi8 complex, No.2009,  
daneshjoo 48 street, daneshgah town, ahvaz

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

6134933357

**Phone**

+98 61 3292 1837

**Fax****Email**

negin.sgr@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Ahvaz University of Medical Sciences

**Full name of responsible person**

Negin Soozangar

**Position**

Dermatology Assistant

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Dermatology

**Street address**

Unit 10, 5th floor, asadi8 complex, No.2009,  
daneshjoo 48 street, daneshgah town, ahvaz

**City**

Ahvaz

**Province**

Khouzestan

**Postal code**

6134933357

**Phone**

+98 61 3292 1837

**Fax****Email**

negin.sgr@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Research data, including anonymized consent forms and before-and-after photos of patients' results, along with basic information including gender and age, will be shared.

**When the data will become available and for how long**

Access begins 6 months after publication of the article.

**To whom data/document is available**

Only for researchers working in academic and scientific institutions

**Under which criteria data/document could be used**

To conduct further studies in this field or other parallel and related studies.

**From where data/document is obtainable**

To receive the documents, please send a request to Dr. Negin Soozangar's email: negin.sgr@gmail.com. If there is no response, please send a request to the address: Dermatology Department Office, 3rd Floor, Imam Hospital, Azadegan Street, Ahvaz, Khuzestan.

**What processes are involved for a request to access data/document**

After registering the request in writing, along with the phone number and details of the applicant, to the email or address mentioned, a response will be received within one week after the necessary checks. The reason for requesting the documents should also be mentioned.

**Comments**